A Phase III Randomized, Double Blind Trial Of Chemoembolization With Or Without Sorafenib In Unresectable Hepatocellular Carcinoma (Hcc) In Patients W
Posted Date: May 15, 2019
- Investigator: Olugbenga Olowokure
- Type of Study: Drug
The purpose of this study is to see if adding the oral chemotherapy pill, sorafenib (Nexavar), to localized chemotherapy to the liver will help patients to live longer than treatment with localized chemotherapy to the liver without sorafenib. Sorafenib is currently approved by the United States Fo
Criteria:
Eligible Patients Must Have Liver Cancer (Hepatocellular Carcinoma) That Is Not Able To Be Removed B
Keywords:
E1208, Gastrointestinal Can, Gi Cancer, Hcc, Unresectable
For More Information:
Uc Cancer Center
513-584-7698
kastla@ucmail.uc.edu